吉非替尼治疗晚期非小细胞肺癌疗效分析

Therapeutic Effect of Gefitinib in the Treatment of Advanced Non-small Cell Lung Cancer

目的探讨吉非替尼对于晚期非小细胞肺癌(NSCLC)患者短期疗效、生活质量及生存期的影响。方法选择2012年2月—2015年3月我院肿瘤科收治的晚期(TNM分期III期b^IV期)NSCLC患者62例作为研究对象。所有患者均口服吉非替尼治疗,对入组对象随访至2017年3月截止,观察生存期,并在治疗6个月后评价其短期疗效、患者生活质量及症状改善状况。结果 62例患者平均生存期为(280.64±10.82)d;治疗3个月后,62例患者中,CR(2例)、PR(10例)、SD(20例)、PD(30例),疾病控制率为51.61%;治疗3个月,本组患者KPS评分为(78.82±9.04)分,较治疗前(54.25±10.71)分提升明显,差异具有统计学意义(P<0.05)。结论应用吉非替尼治疗晚期非小细胞肺癌的不仅短期疗效好,还可提高患者生活质量及改善症状,且生存期较长。

Objective To investigate the effect of gefitinib on short-term efficacy,quality of life and survival in patients with advanced non-small cell lung cancer(NSCLC).Methods From February 2012 to March 2015,62 patients with advanced NSCLC(TNM III stage b^IV stage)admitted in our department of oncology were enrolled.All of the above patients were treated with gefitinib.The patients were followed up March 2017 deadline,survival was observed,and after 6 months of treatment to evaluate its shortterm efficacy,quality of life and symptoms of patients with improved status.Results The average survival time of 62 patients was(280.64±10.82)days.Among 62 patients,CR(2 cases),PR(10 cases),SD(20 cases),PD(30 cases).The disease control rate was 51.61%.After 3 months of treatment,the KPS score of this group was(78.82±9.04)points,significantly higher than that before treatment(54.25±10.71)points,the difference was statistically significant(P<0.05).Conclusion The application of gefitinib in the treatment of advanced non-small cell lung cancer is not only good shortterm efficacy,but also improve the quality of life of patients and improve symptoms,and longer survival.